Chemistry of sulfide deposites of ODP Site 106-649

The Snake Pit active hydrothermal field was discovered at 23°22'N on the Mid-Atlantic Ridge during ODP Leg 106. Among the ten holes drilled in the mound at the foot of an active chimney, only three (649B, 649F, and 649G) had substantial recovery, and produced cores of unconsolidated hydrothermal deposit made up of porous sulfide fragments with minor talc pellets and biological debris, and a few pieces of brassy massive sulfides. Eight representative samples from the 6.5-m-long core from Hole 649B were analyzed for bulk chemistry, both by XRF (major elements) and NAA (trace elements). Major elements average compositions show high Fe (36 wt%), S (37 wt%), and Cu (12 wt%) contents, and minor Zn (6.7 wt%), reflecting a mostly high-temperature deposit. Trace elements are characterized by a high Au content (600 ppb) which could express the maturity of the mound. Mineralogical assemblages show evidence of sequential precipitation, and absence of equilibrium. Major sulfide phases are pyrrhotite, pyrite, Fe, Cu sulfides, marcasite, and sphalerite. Three types of samples are distinguished on the basis of textures and mineral assemblages: type 1, rich in pyrrhotite, with approximately equivalent amounts of Cu, Fe sulfides, and sphalerite and minor pyrite; type 2, rich in Cu, Fe sulfides, which are cubic cubanite with exsolutions and rims of chalcopyrite; and type 3, essentially made up of sphalerite. Type 2 samples likely represent fragments of the inner chimney wall. The presence of talc intergrown with cubic cubanite/chalcopyrite in one big piece from Hole 649G is probably related to mixing of the hydrothermal fluid with seawater.

(106)Ruthenium brachytherapy for retinoblastoma.

PURPOSE: To evaluate the efficacy of (106)Ru plaque brachytherapy for the treatment of retinoblastoma. METHODS AND MATERIALS: We reviewed a retrospective, noncomparative case series of 39 children with retinoblastoma treated with (106)Ru plaques at the Jules-Gonin Eye Hospital between October 1992 and July 2006, with 12 months of follow-up. RESULTS: A total of 63 tumors were treated with (106)Ru brachytherapy in 41 eyes. The median patient age was 27 months. (106)Ru brachytherapy was the first-line treatment for 3 tumors (4.8%), second-line treatment for 13 (20.6%), and salvage treatment for 47 tumors (74.6%) resistant to other treatment modalities. Overall tumor control was achieved in 73% at 1 year. Tumor recurrence at 12 months was observed in 2 (12.5%) of 16 tumors for which (106)Ru brachytherapy was used as the first- or second-line treatment and in 15 (31.9%) of 47 tumors for which (106)Ru brachytherapy was used as salvage treatment. Eye retention was achieved in 76% of cases (31 of 41 eyes). Univariate and multivariate analyses revealed no statistically significant risk factors for tumor recurrence. Radiation complications included retinal detachment in 7 (17.1%), proliferative retinopathy in 1 (2.4%), and subcapsular cataract in 4 (9.7%) of 41 eyes. CONCLUSION: (106)Ru brachytherapy is an effective treatment for retinoblastoma, with few secondary complications. Local vitreous seeding can be successfully treated with (106)Ru brachytherapy.

Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.

Epithelioid sarcoma (ES) is rare with a poor prognosis and for which a loss of INI1 expression has been recently reported. We report a study of 106 cases with clinical, histologic, and immunohistochemical data, including INI1 expression, and follow-up data. Of the 106 cases, 70 were the conventional subtype and 36 the large cell subtype. INI1 was negative in 86 cases (81.1%): 57 (81%) of 70 conventional and 29 (81%) of 36 large cell subtypes. Treatment modalities were available for 76 and follow-up for 80 patients. Of the 80 patients, 43 (54%) experienced metastasis and 25 (31%) died of the disease. Univariate analysis indicated that tumor size and mitotic index were significant for metastasis-free survival, whereas proximal location, tumor size, tumor multifocality, and mitotic index were significant for overall survival. Loss of expression of INI1 is frequent in the conventional and large cell subtypes of ES and can be used as a diagnostic marker, but it has no prognostic impact.

Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.

Age at menarche is a marker of timing of puberty in females. It varies widely between individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes, cardiovascular disease, breast cancer and all-cause mortality. Studies of rare human disorders of puberty and animal models point to a complex hypothalamic-pituitary-hormonal regulation, but the mechanisms that determine pubertal timing and underlie its links to disease risk remain unclear. Here, using genome-wide and custom-genotyping arrays in up to 182,416 women of European descent from 57 studies, we found robust evidence (P < 5 × 10(-8)) for 123 signals at 106 genomic loci associated with age at menarche. Many loci were associated with other pubertal traits in both sexes, and there was substantial overlap with genes implicated in body mass index and various diseases, including rare disorders of puberty. Menarche signals were enriched in imprinted regions, with three loci (DLK1-WDR25, MKRN3-MAGEL2 and KCNK9) demonstrating parent-of-origin-specific associations concordant with known parental expression patterns. Pathway analyses implicated nuclear hormone receptors, particularly retinoic acid and γ-aminobutyric acid-B2 receptor signalling, among novel mechanisms that regulate pubertal timing in humans. Our findings suggest a genetic architecture involving at least hundreds of common variants in the coordinated timing of the pubertal transition.

Friday Facts, June 17, 2011, Vol. 106

Bureau of Nutrition and Health Promotion part of the Iowa Department of Public Health produces of weekly newsletter about the Iowa WIC Program for the State of Iowa citizen.